Pacira BioSciences, Inc.
For the period ended Mar 31, 2026. Filed Apr 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Apr 30, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
The following table shows the “Rule 10b5-1 trading arrangements” and “non-Rule 10b5-1 trading arrangements” (as each term is defined in Item 408(a) of Regulation S-K)adopted by our directors and executive officers during the quarter ended March 31, 2026. No trading arrangements were terminated by our directors and executive officers during the quarter ended March 31, 2026.
| Trading Arrangement | |||||
|---|---|---|---|---|---|
| Name and Position · Action · Date · Rule10b5-1* · Non-Rule10b5-1** · Total Number ofShares to be Sold · ExpirationDate | |||||
| Brendan TeehanChief Commercial Officer | Adopt | 3/5/2026 | x | 8,720 (1) | 2/26/2027 |
| Lauren RikerPrincipal Accounting Officer | Adopt | 3/12/2026 | x | To Be Determined (2) | 12/7/2026 |
- Intended to satisfy the affirmative defense of Rule 10b5-1(c).
** Not intended to satisfy the affirmative defense of Rule 10b5-1(c).
(1) The shares to be sold pursuant to the trading arrangement listed above are dependent on sale prices under the trading arrangement.
(2) The aggregate number of shares to be sold pursuant to the trading arrangement listed above is dependent on, among other things, sale prices under the trading arrangement and the amount of tax withholding required upon the vesting of restricted stock units, and, therefore, is indeterminable at this time.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.